Data as of . Holdings from the fund’s latest public SEC N-PORT filing; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested.
XDNA · Kelly CRISPR & Gene Editing Technology ETF
not published · Themes desk
Open the live card on ETFIQXDNA has no public holdings filing captured yet. Over the year to Sep 4, 2026 the fund returned +0.0% with distributions reinvested against +20.0% for the S&P 500, so a holder was behind by 20.0 pts. It sits 49.2% below its all-time high of Aug 15, 2022.
| Theme (ETFIQ, editorial) | Genomics and biotech innovation |
|---|---|
| Launched | Jan 13, 2022 |
| 3 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +0.0% / +4.7% / −4.7 pts / −2.1 pts |
| 6 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +0.0% / +15.2% / −15.2 pts / −20.2 pts |
| 1 year: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +0.0% / +20.0% / −20.0 pts / −25.6 pts |
| 3 years: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | −10.9% / +78.0% / −88.8 pts / −104.3 pts |
| since launch: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | −48.0% / +76.2% / −124.2 pts / −143.7 pts |
| Below its all-time high (ETFIQ) | −49.2% |
Questions people ask
- Has XDNA beaten the S&P 500?
- Over the year to Sep 4, 2026 XDNA returned +0.0% with distributions reinvested, against +20.0% for the S&P 500, so it finished behind the index by 20.0 points.
Funds near this one
Cite this page. ETFIQ, XDNA on the themes desk, data as of Sep 4, 2026. https://etfiq.com/funds/XDNA.html Free to use with attribution; the underlying files are at Open data.
ETFIQ is an independent publisher of exchange-traded fund data. It is not a fund issuer, broker-dealer or investment adviser, and it makes no recommendations; sort orders and figures are stated arithmetic on published data. Standards · How to read this desk